Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tinidazole · 1 trial · 2 indications
Microbiologic cure of M. genitalium will be determined at a test of cure visit. Microbiologic cure will be defined as a negative test for M. genitalium in a urine specimen using a nucleic acid amplification test.
| Arm | Type | Description |
|---|---|---|
| Tinidazole | EXPERIMENTAL | Single Arm |
| Name | Type | Description |
|---|---|---|
| Tinidazole | DRUG | 2 grams orally on day one followed by 500mg orally twice daily on days 2-10 |
Inclusion Criteria: * ≥18 years of age * Clinical diagnosis of NGU * Urogenital MG documented by a positive NAAT in the prior 7 days * Fluent in English * Assigned male at birth * Attending the PHSKC SHC * Able to provide informed consent * Able to undergo a test of cure (TOC) 21 days after complet...
Tinidazole is an investigational small molecule being studied for the treatment of Mycoplasma Genitalium, a sexually transmitted infection that can cause non-gonococcal urethritis (NGU). It is currently in Phase 2 clinical development and has not been approved for this indication.
Tinidazole is a small molecule antibiotic. Its specific molecular target for Mycoplasma Genitalium is not disclosed in the available information. The drug is being evaluated for its ability to treat this infection, which is a common cause of non-gonococcal urethritis.
Tinidazole is being developed by Hologic, Inc., a company traded on the NASDAQ under the ticker HOLX. Hologic is conducting clinical trials to evaluate the drug's safety and efficacy for treating Mycoplasma Genitalium infections.
Tinidazole is in Phase 2 clinical development for Mycoplasma Genitalium. It is an investigational drug and has not received FDA approval. The ongoing Phase 2 trial is actively recruiting participants in the United States.
Tinidazole is being studied in a single Phase 2 clinical trial with the identifier NCT07088419, titled "Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)". This trial is recruiting 40 male participants aged 18 years and older in the United States.
Tinidazole is a distinct antibiotic agent. While it belongs to the nitroimidazole class of drugs, which includes other antibiotics like metronidazole, it is a separate compound. The available information does not list any alternative names for this drug.